Screener / SEC EDGAR /CIK 0001158895 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Instruments

Lemaitre Vascular Inc LMAT

We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. 10-K, Item 1

Headquarters
Burlington, MA
CEO
George W. LeMaitre
Next results
around Feb 24, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $249.6M through the costs to a net profit of $57.7M · income statement of the 10-K

27% operating margin
Revenue to Gross profit: $178.5MRevenue to Cost of revenue: $71.1MGross profit to Operating profit: $67.9MGross profit to Operating expenses: $110.6MOperating profit to Net profit: $50.5MOperating profit to Tax: $17.4MOther income to Net profit: $7.3MOperating expenses to R&D: $14.1MOperating expenses to Sales, admin & other: $96.5M Revenue: $249.6M REVENUE $249.6M +14% Y/Y Gross profit: $178.5M · 72% margin GROSS PROFIT $178.5M 72% margin · +18% Y/Y Cost of revenue: $71.1M · 28% of revenue COST OF REVENUE $71.1M 28% of revenue Operating profit: $67.9M · 27% margin OPERATING PROFIT $67.9M 27% margin · +30% Y/Y Other income: $7.3M · 3% of revenue OTHER INCOME $7.3M 3% of revenue Operating expenses: $110.6M · 44% of revenue OPERATING EXPENSES $110.6M 44% of revenue Net profit: $57.7M · 23% margin NET PROFIT $57.7M 23% margin · +31% Y/Y Tax: $17.4M · 7% of revenue TAX $17.4M 7% of revenue R&D: $14.1M · 6% of revenue R&D $14.1M 6% of revenue Sales, admin & other: $96.5M · 39% of revenue SALES, ADMIN & OTHER $96.5M 39% of revenue
Gross profit $178.5M 72% margin · +18% Y/Y
Operating profit $67.9M 27% margin · +30% Y/Y
Net profit $57.7M 23% margin · +31% Y/Y
The full income statement, year by year

LMAT among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 13.5%, above 62% of 154 peers (their median 10.4%) REVENUE GROWTH 13.5% · above 62% Gross margin: 72.0%, above 74% of 107 peers (their median 63.4%) GROSS MARGIN 72.0% · above 74% Operating margin: 27.7%, above 89% of 138 peers (their median 9.8%) OPERATING MARGIN 27.7% · above 89% Net margin: 23.5%, above 88% of 153 peers (their median 6.7%) NET MARGIN 23.5% · above 88% FCF margin: 24.9%, above 89% of 144 peers (their median 9.9%) FCF MARGIN 24.9% · above 89% Return on capital: 12.1%, above 70% of 89 peers (their median 9.0%) RETURN ON CAPITAL 12.1% · above 70%
LMAT Peer median Below the median

What changed

37 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

9 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 9 checks found nothing to note

  • Receivables +11.8% ($30.1M to $33.6M) vs revenue +13.5% ($219.9M to $249.6M), -1.7 pts apart
  • Cash from operations $81.3M vs net income $57.7M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: GRANT THORNTON LLP
6 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

37 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 37 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Our business, financial condition, results of operations, cash flows and the trading price of our common stock are subject to numerous risks and uncertainties, including, but not limited to, the following: •We may not be able to maintain our historical profit growth rates, which have been driven by pricing increases, sales force…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Adverse global economic conditions and trade tensions could have a negative effect on our business, results of operations, and financial condition and liquidity. Sustained uncertainty about, or worsening of, global economic conditions and tariffs and escalations of tensions between the United States and its trading partners could result…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Cybersecurity breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The secure processing, storage, maintenance, and transmission of business-critical and confidential information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$161.7M$193.5M$219.9M$249.6M
Net income$20.6M$30.1M$44.0M$57.7M
Operating cash flow$25.4M$36.8M$44.1M$81.3M
Free cash flow$22.1M$29.5M$37.2M$74.5M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$249.6M ▲ 13.5% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Lemaitre Vascular Inc, Burlington, MA · from the 10-K filed Feb 26, 2026

We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific.

Headquarters
Burlington, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LMAT/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.